-- アンソン・リソーシズ(ASX:ASN)は、ユタ州のマウント・フューエル・スカイライン・ガイザー1-25号井の再掘削プログラムにおいて、深度9,189フィートのミシシッピ紀層から採取された掘削泥水から、148ppmのリチウム濃度が検出されたと、月曜日にオーストラリア証券取引所に提出した書類で発表した。 同社によると、深度9,189フィートから9,239フィートのミシシッピ紀リードビル層から、高濃度の掘削泥水サンプルが採取された。3Dモデルによると、ミシシッピ紀のマウント・フューエル・スカイライン・ガイザー層の厚さは650フィートから660フィートと推定される。 同社は、分析結果およびその他のデータはJORC資源量推定値の増加を裏付けるものであり、改訂資源量推定値への組み込みを検討するため、第三者機関に送付したと付け加えた。 同社の株価は、月曜日の取引で2%下落した。
Related Articles
Morgan Stanley Downgrades AES to Equalweight From Overweight, Adjusts Price Target to $15 From $23
AES (AES) has an average rating of hold and mean price target of $15.12, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Compass Therapeutics Tovecimig Study Falls Short on Overall Survival Endpoint in Biliary Tract Cancer; Shares Fall Pre-Bell
Compass Therapeutics (CMPX) reported that its experimental drug tovecimig did not meet the overall survival secondary endpoint in a phase 2/3 study in patients with advanced biliary tract cancer, the company said Monday.Shares of the company fell more than 63% in recent pre-bell activity Monday.The company said that tovecimig plus paclitaxel did not show a statistically significant overall survival benefit versus chemotherapy alone, largely due to high crossover from the control arm and prolonged survival after switching to the drug.However, the study met other key endpoints, including statistically significant improvements in progression-free survival and overall response rate versus paclitaxel alone.Compass Therapeutics plans to meet with the US Food and Drug Administration to discuss the results ahead of a planned biologics license application submission, it added.Price: $1.91, Change: $-3.11, Percent Change: -63.35%
Gold Eases Early Even as the Dollar Falls Ahead of This Week's U.S. Interest Rate Decision
Gold prices eased early on Monday, remaining rangebound even as the dollar fell ahead of the Wednesday interest-rate announcement from the Federal Reserve.Gold for June delivery was last seen down US$26.50 to US$4,714.40 per ounce, remaining within the US$200 range it has been stuck in since the start of the war on Iran, as high oil prices raise concerns over higher inflation and threaten to boost interest rates.The Federal Open Market Committee (FOMC) will make its latest interest-rate decision at the Wednesday afternoon end to its two-day meeting. The CME FedWatch Tool sees a 100% probability the group will leave rates unchanged."Gold remains stuck in neutral within a broad USD 200 range around USD 4,750, with most intraday price action dictated by energy prices and the ebb and flow of headlines from the White House and the Middle East. The FOMC is widely expected to leave rates unchanged on Wednesday," Saxo Bank noted.The dollar was lower early, with the ICE dollar index last seen down 0.28 points to 98.26. Treasury yields rose, with the yield on the two-year note up 1.0 basis points to 3.801%, while the 10-year note was paying 4.321%, up 1.3 points.